Moreover, the FDA also approved pembrolizumab for the first-line treatment of R/M HNSCC patients in combination with platinum and 5-fluorouracil (5FU) and in monotherapy in programmed cell death ligand 1 (PD-L1) expressing patients (Burtness et al., 2019)3. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.